Publication details
Novinky v systémové léčbě pokročilého a metastatického karcinomu žaludku
| Title in English | News in systemic treatment of advanced and metastatic carcinoma of the stomach |
|---|---|
| Authors | |
| Year of publication | 2018 |
| Type | Article in Periodical |
| Magazine / Source | Klinická farmakologie a farmacie |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.solen.cz/artkey/far-201803-0004_Novinky_v_systemove_lecbe_pokrocileho_a_metastatickeho_karcinomu_zaludku.php |
| Doi | http://dx.doi.org/10.36290/far.2018.018 |
| Keywords | gastric cancer; systemic therapy; chemotherapy; target treatment; imunotherapy; predictive markers |
| Description | Although the incidence of gastric cancer progressively decreases, high mortality still persists and stomach cancer is one of themost aggressive diseases. Based on the meta-analysis of the benefit of chemotherapy in palliative treatment, for good combinationregimens with fluorouracil were evaluated oxaliplatin, irinothecan and docetaxel in first-line treatment, and the benefit ofanthracyclines and capecitabine would be assessed as unconvincing. The standard for treatment of the first line in HER-positivecarcinoma has become a combination with trastuzumab; for the II line treatment, however, no further HER receptor blockershave been confirmed as effective. The only effective biological agent for the treatment of the II line is currently evaluated withramucirumab. The benefit of immunotherapy has so far been tested and it appears that further predictors will be needed for thistreatment, including pathological assessment. |